Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

GSK is also running a third phase 3 trial of depemokimab, called NIMBLE, that is exploring the use of the drug in patients switched from Nucala or Fasenra and is also studying it in other Nucala ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.